Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2244)	2/11/2008 2:11:01 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

POTP was up 46.66% & is still up 20% with volume now cloe to 4M , about 8x its ADV bigcharts.marketwatch.com It announced that it has received proxies sufficient to approve the pending merger transaction with DARA BioSciences. & a reverse stock split. At a special meeting on Jan 28, stockholders of DARA approved the merger.POTP will change its name to DARA BioSciences. There is now a NAZ deadline of Feb13 to allow POTP to close the merger with DARA and satisfy the listing criteria.<g> POTP is trying to develop dipeptidyl peptidase inhibitors for use in cancer and type 2 diabetes.Its lead product candidate, talabostat is in PIII for treatment of metastatic NSLC. It is also trying to develop PT-630, a DPP inhibitor for the treatment of type 2 diabetes. The stock trades around 0.75xBV. It is trying to get off the near term DT coming from the Oct 17 H at $0.53 bigcharts.marketwatch.com The Jan 2001 H was $14.60 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2244)	12/1/2008 10:48:32 AM
From: Jibacoa	Respond to of 3722

PRW is up 20% on low volume. That will be the 3rd day on a roll and it is up 100% from its Nov25 L <g> bigcharts.marketwatch.com PRW reported on the black column on its 3rdQ vs. the $0.06 loss in 2007 In Nov it filed a registration statement with the SEC for its previously announced rights offering, when it plans to distribute at no charge to the existing holders of the Company’s common stock on the record date, non-transferable subscription rights to purchase shares of its common stock and Series C warrants. PRW expects to use the proceeds from the offering to complete the submission to the FDA of its NDA for DAVANAT, as well as for general working capital. In Oct it announced a Pre-NDA Meeting had been scheduled with FDA for Dec22 for its DAVANAT on treatment of Late-Stage Colorectal Cas.(DAVANAT is to be co-administered with 5-FU) In pre-clinical and clinical studies, DAVANAT has improved efficacy and reduced toxicity of chemotherapies and biologics. PRW is using its DAVANAT, a galactomannan, to obtain more timely and efficient marketing approval of new formulations of previously approved therapeutics which incorporate the Company’s proprietary drug through Section 505 (b)(2). The FDA has approved galactomannans for other uses, such as oral or topical delivery. DAVANAT mechanism of action is based on binding to lectins. It targets specific lectin receptors on cancer cells. Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis. PRW's pipeline is focused on developing targeted therapeutics to treat cancer, but its technology also is being developed to explore the treatment of liver and kidney fibrosis. Disclosure: I don't own any shares, but with PRW's good spike in Feb2007 keep a watch in its performance. :>) bigcharts.marketwatch.com Bernard